Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 584

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm

Open access
Homma, Shunichi, Thompson, John L.P., Pullicino, Patrick M., Levin, Bruce, Freudenberger, Ronald S., Teerlink, John R., Ammon, Susan E., Graham, Susan, Sacco, Ralph L., Mann, Douglas L., Mohr, J.P., Massie, Barry M., Labovitz, Arthur J., Anker, Stefan D., Lok, Dirk J., Ponikowski, Piotr, Estol, Conrado J., Lip, Gregory Y.H., Di Tullio, Marco R., Sanford, Alexandra R., Mejia, Vilma, Gabriel, Andre P., del Valle, Mirna L., Buchsbaum, Richard·2012·New England Journal of Medicine

Abstract

BACKGROUND: It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm. METHODS: We designed this trial to determine whether warfarin (with a target international normalized ratio of 2.0 to 3.5) or aspirin (at a dose of 325 mg per day) is a better treatment for patients in sinus rhythm who have a reduced left ventricular ejection fraction (LVEF). We followed 2305 patients for up to 6 years (mean [±SD], 3.5±1.8). The primary outcome was the time to the first event in a composite end point of ischemic stroke, intracerebral hemorrhage, or death from any cause. RESULTS: The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P=0.40). Thus, there was no significant overall difference between the two treatments. In a time-varying analysis, the hazard ratio changed over time, slightly favoring warfarin over aspirin by the fourth year of follow-up, but this finding was only marginally significant (P=0.046). Warfarin, as compared with aspirin, was associated with a significant reduction in the rate of ischemic stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P=0.005). The rate of major hemorrhage was 1.78 events per 100 patient-years in the warfarin group as compared with 0.87 in the aspirin group (P<0.001). The rates of intracerebral and intracranial hemorrhage did not differ significantly between the two treatment groups (0.27 events per 100 patient-years with warfarin and 0.22 with aspirin, P=0.82). CONCLUSIONS: Among patients with reduced LVEF who were in sinus rhythm, there was no significant overall difference in the primary outcome between treatment with warfarin and treatment with aspirin. A reduced risk of ischemic stroke with warfarin was offset by an increased risk of major hemorrhage. The choice between warfarin and aspirin should be individualized. (Funded by the National Institute of Neurological Disorders and Stroke; WARCEF ClinicalTrials.gov number, NCT00041938.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1202299

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 584

Metadata

Authors
Homma, S., Thompson, J. L. P., Pullicino, P. M., Levin, B., Freudenberger, R. S., Teerlink, J. R., Ammon, S. E., Graham, S., Sacco, R. L., Mann, D. L., Mohr, J. P., Massie, B. M., Labovitz, A. J., Anker, S. D., Lok, D. J., Ponikowski, P., Estol, C. J., Lip, G. Y. H., Di Tullio, M. R., Sanford, A. R., Mejia, V., Gabriel, A. P., del Valle, M. L., & Buchsbaum, R.
Venue
New England Journal of Medicine
Published
2012-05-17
Volume
366
Issue
20
Pages
1859-1869
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2102355502
Cited by
584
References
27
FWCI
37.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. https://app.cochat.ai/papers/10.1056/nejmoa1202299
The paper
Homma, S., Thompson, J. L. P., Pullicino, P. M., Levin, B., Freudenberger, R. S., Teerlink, J. R., Ammon, S. E., Graham, S., Sacco, R. L., Mann, D. L., Mohr, J. P., Massie, B. M., Labovitz, A. J., Anker, S. D., Lok, D. J., Ponikowski, P., Estol, C. J., Lip, G. Y. H., Di Tullio, M. R., . . . Buchsbaum, R. (2012). Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1202299

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.